Hypoxia increases antibiotic resistance in Pseudomonas aeruginosa. through altering the composition of multidrug efflux pumps.

Size: px
Start display at page:

Download "Hypoxia increases antibiotic resistance in Pseudomonas aeruginosa. through altering the composition of multidrug efflux pumps."

Transcription

1 AAC Accepts, published online ahead of print on 30 January 2012 Antimicrob. Agents Chemother. doi: /aac Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Hypoxia increases antibiotic resistance in Pseudomonas aeruginosa through altering the composition of multidrug efflux pumps. 3 4 Bettina Schaible 1*, Cormac T. Taylor 1 & Kirsten Schaffer Conway Institute, University College Dublin, Belfield & 2 Department of Clinical Microbiology, St. Vincent s University Hospital, Dublin 4, Ireland. 8 9 Running title: Hypoxia induces antibiotic resistance in P. aeruginosa Keywords: Hypoxia, antibiotic resistance Corresponding author: Bettina Schaible Conway Institute University College Dublin Belfield, Dublin 4 Ireland bettina.schaible@ucd.ie 19 Tel: Fax:

2 Abstract Antibiotic resistance is a significant and developing problem in general medical practice and a common clinical complication in cystic fibrosis patients infected with Pseudomonas aeruginosa (P. aeruginosa). Such infections occur within hypoxic mucous deposits in the cystic fibrosis lung, however, little is known about how the hypoxic microenvironment impacts upon pathogen behavior. Here, we investigated the impact of hypoxia on antibiotic resistance in P. aeruginosa. Minimal inhibitory concentrations (MIC) of a selection of antibiotics were determined for P. aeruginosa grown under either normoxic or hypoxic conditions. Messenger RNA expression for resistance-nodulation-cell division (RND) multidrug efflux pump linker proteins were determined by real-time PCR and multidrug efflux pump activity was inhibited using Phe-Arg β naphtylamid dihydrochloride. MIC values of a subset of clinically important P. aeruginosa antibiotics were increased in bacteria incubated in hypoxia when compared with normoxia. Furthermore, hypoxia altered the stoichiometry of multidrug efflux pump linker protein subtype expression and pharmacologic inhibition of these pumps reversed hypoxia-induced antibiotic resistance. We hypothesize that hypoxia increases multidrug resistance in P. aeruginosa by shifting multidrug efflux pump linker protein expression towards a dominance of MexEF-OprN. Thus, microenvironmental hypoxia may significantly contribute to the development of antibiotic resistance in P. aeruginosa infection in cystic fibrosis patients. 44 2

3 Introduction Hypoxia and inflammation are coincidental events in a number of chronic infectious diseases (16). The metabolic demands of infiltrating immune cells and multiplying pathogens along with vascular dysfunction associated with chronic inflammation contribute to tissue hypoxia in such conditions (4). However, rather than simply being a bystander feature of the microenvironment, hypoxia has an important effector role in influencing gene expression in host cells and invading pathogens alike and can significantly impact upon the development of both infection and inflammation (17). While the impact of decreased oxygen tension on bacterial virulence has been investigated for intestinal pathogens such as Shigella flexneri (12), little is known about it s effects on antibiotic resistance in Pseudomonas aeruginosa (P. aeruginosa). Cystic fibrosis is the most common severe autosomal recessive disease in Caucasians. Chronic lung disease is the major determinant of long-term survival in cystic fibrosis patients and P. aeruginosa, an opportunistic pathogen, can cause life threatening infections. Approximately 80% of adult cystic fibrosis patients suffer from pulmonary P. aeruginosa infection and this is associated with increased morbidity and mortality (15). In cystic fibrosis, P. aeruginosa grows within thick mucous secretions which accumulate within the airway lumen and low oxygen permeability of these biofilms results in the establishment of a hypoxic microenvironment (20). Treatment of P. aeruginosa infections in cystic fibrosis is complicated by antibiotic resistance and eradication of P. aeruginosa from the cystic fibrosis lung 3

4 is generally unachievable in persistent infection (15). As development of new antimicrobial agents has diminished over the last decades, antimicrobial resistance is a growing global problem and new strategies to combat panresistant bacteria are required. A key mechanism of antibiotic resistance is via the expulsion of antibiotics through multidrug resistance (MDR) efflux systems belonging to the resistance nodulation division (RND). These pumps play an important role in intrinsic and acquired multidrug resistance (14). Four such pumps, MexAB-OprM, MexCD-OprJ, MexEF-OprN and MexXY-OprM have been well characterized in P. aeruginosa. While increased antibiotic resistance has been previously reported for P. aeruginosa grown in anaerobic conditions or in biofilms (19), in this study we investigated whether hypoxia, independent of the complex environment of the biofilm, influences antibiotic resistance of P. aeruginosa. A more detailed understanding of the mechanisms of P. aeruginosa antibiotic resistance in cystic fibrosis lung disease will identify new therapeutic targets for antimicrobial therapy. 84 4

5 85 Materials and Methods Bacterial strains and growth conditions The P. aeruginosa control strain (ATCC 27853) and clinical strains from chronically infected cystic fibrosis patients (S8263, S8269, S8276, S8279) were cultured in cation adjusted Mueller Hinton II broth (MHB II) (Becton Dickenson, Microbiology Systems, Cockeysvill, MD). The clinical strain S8263 was resistant to all routinely used anti-pseudomonal antibiotics (Ceftazidime, Piperacillin/tazobactam, Meropenem, Aztreonam, Tobramycin, Gentamicin, Amikacin, Ciprofloxacin). The clinical strains S8269 and S8276 were susceptible to all tested antibiotics whereas S8279 showed a mixed antibiotic susceptibility pattern. All clinical isolates were cultured from sputum specimen of cystic fibrosis patients for at least 1 year. Bacteria were incubated at 30ºC (for analysis of RND multidrug efflux pump expression) or 37ºC (for antibiotic resistance) in normoxia (21% oxygen) or hypoxia (1% oxygen) in a hypoxia chamber (INVIVO Hypoxia Workstation, Ruskinn Technology Limited, Brigend, UK) Antimicrobial susceptibility testing Antibiotic susceptibility testing was performed by microbroth dilution using Sensititre susceptibility plate GNX 2F (Trek diagnostic systems, East Grinstead, UK). To determine the role of efflux pumps in antimicrobial susceptibility, the pump inhibitor, Phe-Arg β naphtylamid dihydrochloride (20 µg/ml endconcentration) (Sigma-Aldrich, Dorset, UK), was used (8). To inhibit hydroxylases, Dimethyloxalylglycine (DMOG, 1mM; Caymen Chemicals, Ann 5

6 Arbor, MI) was used. Dimethylsulfoxide (DMSO, Sigma-Aldrich, Dorset, UK) was used as a vehicle control Analysis of RND multidrug efflux pump expression levels 6 ml of pre-conditioned MHB II media was inoculated with 3 x 10 8 bacteria and incubated for 6-24 h in either normoxia or hypoxia. Bacteria were harvested by centrifugation for 2.5 min at 15,000 rpm. Total RNA was isolated with the RiboPureTM-Bacteria kit (Ambion, Texas, USA) according to the manufacturer s instructions. Real time quantification of cdna was carried out on an ABI PRISM 7900HT Sequence Detection System (Applied Biosystems, Warrington, UK) using the Syber Green PCR Master Mix (2x). Primers for partial amplification of genes encoding the membrane fusion proteins MexA, MexC, MexE, MexX and rpsl were used as puplished before (7). The PCR reaction was run with 2 min at 50ºC, 10 min at 95ºC followed by 40 cycles with 15s at 95ºC and 1 min at 60ºC. Control samples without cdna template or reverse transcriptase were run in parallel. Differences in the amount of starting material were controlled by normalization to the ribosomal rpsl gene. Data were normalized for each gene and presented as ratio of mexe/mexc and mexe/mexa Statistical analysis MIC values are presented as descriptive statistics and MICs were compared with the Kruskal-Wallis test / Duncan posttest (Prism 5) (10). RND multidrug efflux pump expression levels were compared using an unpaired, 2-tailed Student s t- test. p values < 0.05 were considered statistically significant. 6

7 Results P. aeruginosa grown in hypoxia displays increased antibiotic resistance. P. aeruginosa formed confluent monolayers on Mueller Hinton plates during overnight incubation in either normoxia or hypoxia. Under hypoxic conditions P. aeruginosa grew as colorless colonies rather than as standard green colonies, indicating impaired pyocyanin production during growth under hypoxic conditions (Figure 1A). We investigated P. aeruginosa susceptibility to a range of antibiotics in hypoxia compared to normoxia using microbroth dilution plates. MIC values for 21 antibiotics were determined following exposure to either normoxia or hypoxia. Among antibiotics tested by the microbroth dilution method, penicillin and cephalosporin antibiotics demonstrated increased MIC values in hypoxia when compared to normoxia (Figure 1B). These antibiotics included Cefotaxime (FOT), Ceftazidime (TAZ), Cefepime (FEP) Aztreonam (AZT), Ticarcillin / clavulanic acid (TIM) and Piperacillin / tazobactam (P/T) (Figure 1B). Other antibiotics tested including aminoglycosides, carbapenems, polymyxins, quinolones and tetracyclines showed similar MIC values in both normoxic and hypoxic cultures (Figure 1B) Hypoxia differentially alters multidrug efflux pump linker protein expression in P. aeruginosa. We have previously observed that hypoxia affects MDR1 gene expression and chemotherapeutic drug resistance in mammalian cells (5). An antimicrobial resistance mechanism exploited by P. aeruginosa and affecting various antibiotic classes is achieved through the expression of bacterial multidrug efflux pumps. 7

8 Therefore we investigated whether hypoxia-induced multidrug efflux pump expression may contribute to the changes in antibiotic susceptibility in P. aeruginosa. For the analysis of pump expression we used quantitative real-time PCR. Correlation between mrna expression and efflux protein expression has been previously demonstrated (21). Expression levels of four MDR efflux pumps were analyzed following 6-24 hours exposure to normoxia or hypoxia. Interestingly, the stoichiometry of pump linker protein expression changed to dominance of MexE expression over MexA and MexC expression following either 6 or 24 hours hypoxia (Figure 2A and 2B). This was primarily due to decreased MexA and MexC expression with MexE demonstrating sustained expression. Expression of the MexX linker protein gene could not be detected under these conditions (data not shown). To evaluate whether clinical P. aeruginosa strains isolated from cystic fibrosis patients demonstrated a similar change in pump isoform stoichiometry, we evaluated MexA, MexC and MexE pump expression in response to hypoxia in four P. aeruginosa strains isolated from cystic fibrosis patients with different antibiotic susceptibility profiles. All cystic fibrosis patients were chronically infected with P. aeruginosa for more than 1 year. Three of the four cystic fibrosis clinical isolates investigated in this study revealed similar changes in pump stoichiometry in response to hypoxia (Figure 2C) Increased MIC values in hypoxia are normalized by the multidrug efflux pump inhibitor Phe-Arg β naphtylamid dihydrochloride. 8

9 To investigate the existence of a functional link between antibiotic resistance and changed efflux pump activity in hypoxia, we used Phe-Arg β naphtylamid dihydrochloride, an inhibitor of RND efflux pumps (8). Phe-Arg β naphtylamid dihydrochloride reversed hypoxia-induced antibiotic resistance in P. aeruginosa in a selection of β -lactam antibiotics (Figure 3). This led us to hypothesize, that changes in efflux pump activity contributed to increased antibiotic resistance in hypoxia. MIC values in normoxia remained unchanged in the presence of the pump inhibitor (data not shown) Antibiotic susceptibility changes in hypoxia are not mediated by inactivation of hydroxylase activity. In mammalian cells a key signaling event in response to hypoxia is the inhibition of oxygen-dependent hydroxylases leading to activation of the hypoxia inducible factor (HIF) and downstream activation of HIF responsive genes (9). Inhibition of such hydroxylases can be achieved by exposure of cells to DMOG, a nonspecific hydroxylase inhibitor (6). While multiple hydroxylases have been described in several microbes including P. aeruginosa (18) their role in oxygen sensing in the HIF pathway is thought to be restricted to metazoans (11). We investigated if hypoxia-induced changes in MIC values can be mimicked by exposure of bacteria to DMOG. There was no difference between antibiotic susceptibilities between untreated cells and cells treated with DMOG, indicating that 2-oxoglutarate-dependent hydroxylase inhibition did not participate in hypoxia mediated changes in antibiotic susceptibilities (Figure 4). These data are 9

10 consistent with the report of HIF hydroxylases not being primary oxygen sensors in bacteria (11) Discussion Hypoxia has been shown to be an important modulator of bacterial virulence of the intestinal pathogen Shigella Flexneri (12). In chronic infection of the CF lung, P. aeruginosa produces alginate and grows in dense bacterial populations forming mucoid biofilms (1). Complex microbial communities including anaerobic bacteria have been detected in sputa from CF patients (3). Although decreased oxygen tensions have been demonstrated in mucous layers in the CF lung, the effects of hypoxia on antibiotic resistance has not been investigated independent of biofilm formation. Our data show that exposure to hypoxia induces selective antibiotic resistance in P. aeruginosa. Antibiotic resistance of P. aeruginosa in response to hypoxia may not only be important for the treatment of infections in CF lung disease, but also for the management of infections in other chronic respiratory diseases such as bronchiectasis and COPD. In these diseases, chronic inflammation with remodeling of lung tissue and excessive mucous production generates comparable growth conditions to CF and not surprisingly P. aeruginosa is one of the major bacterial pathogens encountered. The analysis of RND efflux pump expression levels in P. aeruginosa revealed a shift in pump expression towards MexEF-OprN under hypoxic conditions in the ATCC strain as well as in 3 out of 4 clinical isolates of P. aeruginosa from CF patients. The β-lactam antibiotics (Aztreonam, Ceftazidime), β-lactam inhibitor combinations (Piperacillin/Tazobactam), tetracyclines and trimethoprim 10

11 have all been shown to be substrates for the MDR efflux pumps MexAB-OprM, MexCD-OprJ and MexEF-OprN (14). As aminoglycosides are believed to be exclusively transported by MexXY-OprM (14), it was not surprising that no effect of hypoxia on tobramycin susceptibilities was observed as we could not detect MexXY-OprM. The failure of hypoxia to increase Ciprofloxacin MICs was surprising, as Ciprofloxacin had been described as a substrate for all three pumps MexAB-OprM, MexCD-OprJ and MexEF-OprN (14). One potential explanation for this phenomenon could be differences in substrate specificity of pumps expressed by various P. aeruginosa strains. As altered efflux pump expression is one of a number of antibiotic resistance mechanisms used by P. aeruginosa, we cannot exclude the possibility that other bacterial resistance mechanisms are also affected by hypoxia. Normalization of raised MIC values in the presence of the efflux pump inhibitor indicates that alterations in efflux pump activities are indeed associated with the observed changes in antimicrobial susceptibility. Altered expression of bacterial RND efflux pumps has been seen in response to exposure to antimicrobials in vivo and in vitro (2, 13), where antibiotic exposure selects for mutation events in genetic regulators suppressing pump expression. Clinical isolates with increased efflux pump expression without identifiable regulatory mutations had been identified before (2), and no inducers of efflux pump expression apart from substrate exposure have been described so far. Here we describe hypoxia as a novel regulator of RND efflux pumps in P. aeruginosa. 11

12 Hydroxylases are key regulatory elements in the cellular response of eukaryotic cells to hypoxia. In P. aeruginosa pharmacologic hydroxylase inhibition failed to increase MIC values compared to normoxia, suggesting that raised MIC levels in hypoxia are independent of hydroxylase activity. As secondary metabolites have been postulated to be the natural substrates for the pumps (14) it is possible that efflux pump genes contain hypoxia responsive elements as part of the bacterial adaptive response to hypoxia. Thus the extrusion of antibiotics via MDR efflux pumps in response to hypoxia could be a secondary effect of the bacterial metabolism adapting to decreased oxygen values. Our finding suggests that bacterial isolates could look sensitive in vitro on testing in the laboratory, but behave resistant in vivo once they encounter hypoxic environments. This could be one factor explaining clinical treatment failure with appropriate antibiotics, which is observed frequently in the management of chronic respiratory infections Acknowledgements This work was supported by grants from the Marie Curie Foundation, Irish Research Council for Science, Engineering & Technology and Science Foundation Ireland Transparency declaration None to declare

13 References 1. Alvarez-Ortega, C., and C. S. Harwood Responses of Pseudomonas aeruginosa to low oxygen indicate that growth in the cystic fibrosis lung is by aerobic respiration. Mol Microbiol 65: Beinlich, K. L., R. Chuanchuen, and H. P. Schweizer Contribution of multidrug efflux pumps to multiple antibiotic resistance in veterinary clinical isolates of Pseudomonas aeruginosa. FEMS Microbiol Lett 198: Bittar, F., H. Richet, J. C. Dubus, M. Reynaud-Gaubert, N. Stremler, J. Sarles, D. Raoult, and J. M. Rolain Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. PLoS One 3:e Colgan, S. P., and C. T. Taylor Hypoxia: an alarm signal during intestinal inflammation. Nat Rev Gastroenterol Hepatol 7: Comerford, K. M., T. J. Wallace, J. Karhausen, N. A. Louis, M. C. Montalto, and S. P. Colgan Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62: Cummins, E. P., F. Seeballuck, S. J. Keely, N. E. Mangan, J. J. Callanan, P. G. Fallon, and C. T. Taylor The hydroxylase inhibitor dimethyloxalylglycine is protective in a murine model of colitis. Gastroenterology 134:

14 Dumas, J. L., C. van Delden, K. Perron, and T. Kohler Analysis of antibiotic resistance gene expression in Pseudomonas aeruginosa by quantitative real-time-pcr. FEMS Microbiol Lett 254: Henrichfreise, B., I. Wiegand, W. Pfister, and B. Wiedemann Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation. Antimicrob Agents Chemother 51: Kaelin, W. G., Jr., and P. J. Ratcliffe Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 30: Kowalski, R. P., K. A. Yates, E. G. Romanowski, L. M. Karenchak, F. S. Mah, and Y. J. Gordon An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data. Ophthalmology 112: Loenarz, C., M. L. Coleman, A. Boleininger, B. Schierwater, P. W. Holland, P. J. Ratcliffe, and C. J. Schofield The hypoxiainducible transcription factor pathway regulates oxygen sensing in the simplest animal, Trichoplax adhaerens. EMBO Rep 12: Marteyn, B., N. P. West, D. F. Browning, J. A. Cole, J. G. Shaw, F. Palm, J. Mounier, M. C. Prevost, P. Sansonetti, and C. M. Tang Modulation of Shigella virulence in response to available oxygen in vivo. Nature 465:

15 Poole, K., N. Gotoh, H. Tsujimoto, Q. Zhao, A. Wada, T. Yamasaki, S. Neshat, J. Yamagishi, X. Z. Li, and T. Nishino Overexpression of the mexc-mexd-oprj efflux operon in nfxb-type multidrug-resistant strains of Pseudomonas aeruginosa. Mol Microbiol 21: Poole, K., and R. Srikumar Multidrug efflux in Pseudomonas aeruginosa: components, mechanisms and clinical significance. Curr Top Med Chem 1: Ratjen, F., and G. Döring Cystic fibrosis. The Lancet 361: Schaible, B., K. Schaffer, and C. T. Taylor Hypoxia, innate immunity and infection in the lung. Respir Physiol Neurobiol 174: Taylor, C. T Interdependent roles for hypoxia inducible factor and nuclear factor-kappab in hypoxic inflammation. J Physiol 586: van Berkel, W. J., N. M. Kamerbeek, and M. W. Fraaije Flavoprotein monooxygenases, a diverse class of oxidative biocatalysts. J Biotechnol 124: Walters, M. C., 3rd, F. Roe, A. Bugnicourt, M. J. Franklin, and P. S. Stewart Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrob Agents Chemother 47: Worlitzsch, D., R. Tarran, M. Ulrich, U. Schwab, A. Cekici, K. C. Meyer, P. Birrer, G. Bellon, J. Berger, T. Weiss, K. Botzenhart, J. R. Yankaskas, S. Randell, R. C. Boucher, and G. Doring Effects of 15

16 reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 109: Yoneda, K., H. Chikumi, T. Murata, N. Gotoh, H. Yamamoto, H. Fujiwara, T. Nishino, and E. Shimizu Measurement of Pseudomonas aeruginosa multidrug efflux pumps by quantitative real-time polymerase chain reaction. FEMS Microbiol Lett 243:

17 340 Figure legends Figure 1: Altered antibiotic resistance in P. aeruginosa under hypoxic conditions. A: Mueller Hinton agar plates were inoculated with ATCC and grown for 20h in a normoxic (N) or hypoxic (H; 1% oxygen) environment. B: MIC determination of ATCC at 21% (N) and 1% oxygen (H) by microbroth dilution of 21 antibiotics (AMI: Amikacin; GEN: Gentamicin; TOB: Tobramycin; FOT: Cefotaxime; TAZ: Ceftazidime; FEP: Cefepime; AZT: Aztreonam; TIM: Ticarcillin /clavulanic acid; P/T: Piperacillin / tazobactam; MERO: Meropenem; ETP: Ertapenem; DOR: Doripenem; IMI: Imipenem; COL: Colistin; POL: Polymicin B; LEVO: Levofloxacin; CIP: Ciprofloxacin; DOX: Doxycycline; MIN: Minocycline; TGC: Tigecycline; SXT: Trimethoprim / sulfamethoxazole) (Sensititre susceptibility plate GNX2F) Data represent mean ± SEM MIC for n=3 independent experiments Figure 2: Altered stoichiometry of RND multidrug efflux pump composition under hypoxic conditions. Investigation of the gene expression of the RND multidrug efflux pumps MexAB- OprM, MexCD-OprJ and MexEF-OprN in P. aeruginosa in normoxia (N) and hypoxia (H) by Real time PCR for the respective linker molecules (mexa, mexc and mexe). A and B: ATCC were grown in N and H for 6h (A) and 24h (B). Gene expression of mexa, mexc and mexe were detected by Real time PCR. Relative 17

18 gene expression was normalized and expressed as a ratio of mexe/mexa and mexe/mexc. Values are expressed as mean ± SEM for n=3 independent experiments (* p < 0.05). C: clinical P. aeruginosa strains were exposed to N and H for 6h, gene expression of the linker molecules were detected by Real time PCR. Relative gene expression was normalized within each gene and expressed as a ratio of mexe/mexa and mexe/mexc. Values are expressed as mean ± SEM for n=2 independent experiments (* p < 0.05).. Figure 3: Increased antibiotic resistance in hypoxia is reversed by a multidrug efflux pump inhibitor. MIC determination of ATCC by microbroth dilution (Sensititre susceptibility plate GNX2F) in normoxia (N), hypoxia (H) and hypoxia in the presence of the efflux pump inhibitor (N+EPI) Phe-Arg β naphtylamid dihydrochloride (20µg/ml). A selection of CF relevant antibiotics where EPI decreased MIC in hypoxia is shown. Values are expressed as mean ± SEM for n=3 independent experiments (* p < 0.05) Figure 4: Hydroxylase inhibition fails to increase antibiotic resistance MIC determination of ATCC by microbroth dilution (Sensititre susceptibility plate GNX2F) in the presence of the hydroxylase inhibitor DMOG (1 mm) or the vehicle control (DMSO). Data represent mean MIC ± SEM of n=3 independent experiments. 18

19

20

21

22

Translocation Studies Mid-Term Review (MTR) Meeting Marseille, France

Translocation Studies Mid-Term Review (MTR) Meeting Marseille, France Marie Curie Actions Research Training Networks (RTN) Translocation Studies Mid-Term Review (MTR) Meeting Marseille, France F. Vidal-Aroca, M.G.P. Page and J. Dreier Background Deteriorating situation regarding

More information

Role of efflux pump inhibitor in decreasing antibiotic cross-resistance of Pseudomonas aeruginosa in a burn hospital in Iran

Role of efflux pump inhibitor in decreasing antibiotic cross-resistance of Pseudomonas aeruginosa in a burn hospital in Iran Original Article Role of efflux pump inhibitor in decreasing antibiotic cross-resistance of Pseudomonas aeruginosa in a burn hospital in Iran Mahshid Talebi-Taher 1, Ali Majidpour 1, Abbas Gholami 2, Samira

More information

Infection & Chemotherapy. Original Article

Infection & Chemotherapy. Original Article Original Article http://dx.doi.org/10.3947/ic.2015.47.2.98 Infect Chemother 2015;47(2):98-104 ISSN 2093-2340 (Print) ISSN 2092-6448 (Online) Infection & Chemotherapy Spread of Efflux Pump Overexpressing-Mediated

More information

Report on susceptibility of Salmonella serotypes in Belgium Vicky Jasson

Report on susceptibility of Salmonella serotypes in Belgium Vicky Jasson CODA-CERVA Report on susceptibility of Salmonella serotypes in Belgium 2014. Vicky Jasson Veterinary and Agrochemical Research Centre 1 Introduction Salmonella is one of the most important bacterial zoonotic

More information

Annual Surveillance Summary: Pseudomonas aeruginosa Infections in the Military Health System (MHS), 2016

Annual Surveillance Summary: Pseudomonas aeruginosa Infections in the Military Health System (MHS), 2016 Annual Surveillance Summary: Pseudomonas aeruginosa Infections in the Military Health System (MHS), 2016 Sarah Gierhart and Uzo Chukwuma Approved for public release. Distribution is unlimited. The views

More information

Affinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED

Affinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED AAC Accepts, published online ahead of print on February 00 Antimicrob. Agents Chemother. doi:./aac.01-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights

More information

In vitro assessment of dual drug combinations to inhibit growth of Neisseria gonorrhoeae

In vitro assessment of dual drug combinations to inhibit growth of Neisseria gonorrhoeae AAC Accepted Manuscript Posted Online 26 January 2015 Antimicrob. Agents Chemother. doi:10.1128/aac.04127-14 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 In vitro assessment

More information

Development of Resistance mechanisms in Pseudomonas aeruginosa

Development of Resistance mechanisms in Pseudomonas aeruginosa Development of Resistance mechanisms in Pseudomonas aeruginosa Luis Martínez Martínez ervice of Microbiology University Hospital Marqués de Valdecilla antander, pain 5th ECMID chool, antander June 2006

More information

Other β-lactam. A. Carbapenems:

Other β-lactam. A. Carbapenems: A. Carbapenems: Other β-lactam Carbapenems are synthetic β-lactam antibiotics Differ in structure from the penicillins in that the sulfur atom of the thiazolidine ring. Imipenem, meropenem, doripenem,

More information

Annual Surveillance Summary: Pseudomonas aeruginosa Infections in the Military Health System (MHS), 2017

Annual Surveillance Summary: Pseudomonas aeruginosa Infections in the Military Health System (MHS), 2017 i Annual Surveillance Summary: Pseudomonas aeruginosa Infections in the Military Health System (MHS), 2017 Jessica R. Spencer and Uzo Chukwuma Approved for public release. Distribution is unlimited. The

More information

Received 10 January 2005; returned 8 February 2005; revised 23 March 2005; accepted 5 April 2005

Received 10 January 2005; returned 8 February 2005; revised 23 March 2005; accepted 5 April 2005 Journal of Antimicrobial Chemotherapy (2005) 55, 921 927 doi:10.1093/jac/dki146 Advance Access publication 9 May 2005 Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute

More information

Chronic Respiratory Infections by Mucoid Carbapenemase-Producing. Pseudomonas aeruginosa: a New Potential Public Health Problem ACCEPTED

Chronic Respiratory Infections by Mucoid Carbapenemase-Producing. Pseudomonas aeruginosa: a New Potential Public Health Problem ACCEPTED AAC Accepts, published online ahead of print on 7 April 2008 Antimicrob. Agents Chemother. doi:10.1128/aac.00076-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions.

More information

Discussion points CLSI M100 S19 Update. #1 format of tables has changed. #2 non susceptible category

Discussion points CLSI M100 S19 Update. #1 format of tables has changed. #2 non susceptible category Discussion points 2009 CLSI M100 S19 Update Nebraska Public Health Laboratory Changes most important to routine antimicrobial susceptibility testing. Documents available Janet Hindler discussion slide

More information

Report: antimicrobial resistance in commensal E. coli from poultry, pigs, cows and veal calves. 2013

Report: antimicrobial resistance in commensal E. coli from poultry, pigs, cows and veal calves. 2013 Veterinary and Agrochemical Research Centre Report: antimicrobial resistance in commensal E. coli from poultry, pigs, cows and veal calves. 2013 1 Introduction Commensal E. coli are regarded as general

More information

University of Alberta Hospital Antibiogram for 2007 and 2008 Division of Medical Microbiology Department of Laboratory Medicine and Pathology

University of Alberta Hospital Antibiogram for 2007 and 2008 Division of Medical Microbiology Department of Laboratory Medicine and Pathology University of Alberta Hospital Antibiogram for 2007 and 2008 Division of Medical Microbiology Department of Laboratory Medicine and Pathology This material is supported in part by unrestricted educational

More information

MexXY efflux pump overexpression and aminoglycoside resistance in cystic fibrosis isolates of Pseudomonas aeruginosa from chronic infections.

MexXY efflux pump overexpression and aminoglycoside resistance in cystic fibrosis isolates of Pseudomonas aeruginosa from chronic infections. Canadian Journal of Microbiology MexXY efflux pump overexpression and aminoglycoside resistance in cystic fibrosis isolates of Pseudomonas aeruginosa from chronic infections. Journal: Canadian Journal

More information

Efflux Pumps, OprD Porin, AmpC -Lactamase, and Multiresistance in Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients

Efflux Pumps, OprD Porin, AmpC -Lactamase, and Multiresistance in Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 2010, p. 2219 2224 Vol. 54, No. 5 0066-4804/10/$12.00 doi:10.1128/aac.00816-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Efflux

More information

PRESENCE OF ACINETOBACTER BAUMANNII IN NATURAL ENVIRONMENT IN CROATIA

PRESENCE OF ACINETOBACTER BAUMANNII IN NATURAL ENVIRONMENT IN CROATIA PRESENCE OF ACINETOBACTER BAUMANNII IN NATURAL ENVIRONMENT IN CROATIA Hrenović Jasna 1, Durn Goran 2, Hunjak Blaženka 3, Goić-Barišić Ivana 4, Kazazić Snježana 5 1 University of Zagreb, Faculty of Science,

More information

Methodological and interpretative problems in antimicrobial susceptiblity tests of P. aeruginosa

Methodological and interpretative problems in antimicrobial susceptiblity tests of P. aeruginosa Methodological and interpretative problems in antimicrobial susceptiblity tests of P. aeruginosa Y. Glupczynski Laboratoire de bactériologie Cliniques Universitaires UCL de Mont-Godinne Université Catholique

More information

Antibiotic Treatment of GNR MDR Infections. Stan Deresinski

Antibiotic Treatment of GNR MDR Infections. Stan Deresinski Antibiotic Treatment of GNR MDR Infections Stan Deresinski Kucers: The Use of Antibiotics 1st Edition 1972 392 pages Kucers: The Use of Antibiotics 7 th Edition 2017 5338 pages Carbapenem Susceptibility

More information

Shirin Abadi, B.Sc.(Pharm.), ACPR, Pharm.D. Clinical Pharmacy Specialist & Pharmacy Education Coordinator, BC Cancer Agency Clinical Associate

Shirin Abadi, B.Sc.(Pharm.), ACPR, Pharm.D. Clinical Pharmacy Specialist & Pharmacy Education Coordinator, BC Cancer Agency Clinical Associate Shirin Abadi, B.Sc.(Pharm.), ACPR, Pharm.D. Clinical Pharmacy Specialist & Pharmacy Education Coordinator, BC Cancer Agency Clinical Associate Professor of Pharmacy & Associate Member of Medicine, UBC

More information

A Snapshot of Colistin Use in South-East Europe and Particularly in Greece

A Snapshot of Colistin Use in South-East Europe and Particularly in Greece A Snapshot of Colistin Use in South-East Europe and Particularly in Greece Helen Giamarellou 02.05.2013 When Greek Physicians Prescribe Colistin? It is mainly prescribed in the ICU for VAP, bacteremia

More information

Veterinary and Agrochemical Research Centre

Veterinary and Agrochemical Research Centre Veterinary and Agrochemical Research Centre Report on susceptibility of Salmonella serotypes in Belgium. P. Butaye Susceptibility of Salmonella strains was assessed by MIC determination using Sensititer

More information

Laboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator

Laboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator Nebraska Public Health Laboratory 2008 CLSI M100-S18 update Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator Agenda Discuss 2008 M100- S18

More information

Expert rules. for Gram-negatives

Expert rules. for Gram-negatives Academic Perspective in Expert rules Emerging Issues of Resistance in Gram-ve Bacteria for Gram-negatives Trevor Winstanley Sheffield Teaching Hospitals Presented on behalf of David Livermore University

More information

Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients

Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients ORIGINAL ARTICLE BACTERIOLOGY Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients L. Zamorano 1, C. Juan 1, A.

More information

The clinical implication and prognostic predictors of Tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii

The clinical implication and prognostic predictors of Tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii Journal of Infection (2011) 63, 351e361 The clinical implication and prognostic predictors of Tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii R 陳南丞 VS 余文良醫師 本檔僅供內部教學使用檔案內所使用之照片之版權仍屬於原期刊公開使用時,

More information

Marcos I. Restrepo, MD, MSc, FCCP

Marcos I. Restrepo, MD, MSc, FCCP Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS for your personal use only, as submitted by the author.

More information

Downloaded from ismj.bpums.ac.ir at 10: on Friday March 8th 2019

Downloaded from ismj.bpums.ac.ir at 10: on Friday March 8th 2019 - ( ) - * :... (MDR) (ESBLs: Extended-Spectrum Beta Lactamases). :.. (CLSI:Clinical and Laboratory Standards Institute). ESBL. combined disk method ESBL : / / / / / B / ( /). / / combined disk method.

More information

Multidrug Resistant Pseudomonas aeruginosa. Presenter: Andrew Webb Block Lecturer: George Zhanel Date: 10 January 2019

Multidrug Resistant Pseudomonas aeruginosa. Presenter: Andrew Webb Block Lecturer: George Zhanel Date: 10 January 2019 Multidrug Resistant Pseudomonas aeruginosa Presenter: Andrew Webb Block Lecturer: George Zhanel Date: 10 January 2019 1 Pseudomonas aeruginosa Not a member of human microbiome Inhabitant of soil and moist

More information

PK/PD degli antibiotici utilizzati nella sepsi

PK/PD degli antibiotici utilizzati nella sepsi PK/PD degli antibiotici utilizzati nella sepsi Dario Cattaneo, U.O. Farmacologia Clinica ASST Fatebenefratelli Sacco, Milano Bergamo, città alta Variability of antibiotic concentrations in critically ill

More information

In Vitro Susceptibility Pattern of Cephalosporin- Resistant Gram-Negative Bacteria

In Vitro Susceptibility Pattern of Cephalosporin- Resistant Gram-Negative Bacteria In Vitro Susceptibility Pattern of Cephalosporin- Resistant Gram-Negative Bacteria Warunee Punpanich MD*, Worraporn Tantichattanon MD**, Siriporn Wongwatcharapaiboon MD**, Vipa Treeratweeraphong BSc, MSc***

More information

Conessine as a novel inhibitor of multidrug efflux pump systems in Pseudomonas aeruginosa

Conessine as a novel inhibitor of multidrug efflux pump systems in Pseudomonas aeruginosa Siriyong et al. BMC Complementary and Alternative Medicine (2017) 17:405 DOI 10.1186/s12906-017-1913-y RESEARCH ARTICLE Open Access Conessine as a novel inhibitor of multidrug efflux pump systems in Pseudomonas

More information

ST11 KPC-2 Klebsiella pneumoniae detected in Taiwan

ST11 KPC-2 Klebsiella pneumoniae detected in Taiwan AAC Accepts, published online ahead of print on 30 January 2012 Antimicrob. Agents Chemother. doi:10.1128/aac.05576-11 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5

More information

The Occurrence of (MDR/MDS) Pseudomonas aeruginosa among Nosocomial and Community Acquired Infections in and around Coimbatore, India

The Occurrence of (MDR/MDS) Pseudomonas aeruginosa among Nosocomial and Community Acquired Infections in and around Coimbatore, India ISSN: 2319-7706 Volume 4 Number 11 (2015) pp. 753-761 http://www.ijcmas.com Original Research Article The Occurrence of (MDR/MDS) Pseudomonas aeruginosa among Nosocomial and Community Acquired Infections

More information

This material is supported in part by unrestricted educational grants from: Abbott, Bayer HealthCare, Merck Frosst, Roche Diagnostics, and Wyeth Inc.

This material is supported in part by unrestricted educational grants from: Abbott, Bayer HealthCare, Merck Frosst, Roche Diagnostics, and Wyeth Inc. Division of Medical Microbiology Department of Laboratory Medicine and Pathology University of Alberta Hospital and Stollery Children's Hospital Antibiogram 2006 This material is supported in part by unrestricted

More information

Overcoming the PosESBLities of Enterobacteriaceae Resistance

Overcoming the PosESBLities of Enterobacteriaceae Resistance Overcoming the PosESBLities of Enterobacteriaceae Resistance Review of current treatment options Jamie Reed, PharmD Pharmacy Grand Rounds August 28, 2018 Rochester, MN 2018 MFMER slide-1 Disclosure No

More information

Breakpoints for Predicting Pseudomonas aeruginosa Susceptibility to Inhaled Tobramycin in Cystic Fibrosis Patients: Use of High-Range Etest Strips

Breakpoints for Predicting Pseudomonas aeruginosa Susceptibility to Inhaled Tobramycin in Cystic Fibrosis Patients: Use of High-Range Etest Strips JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2005, p. 4480 4485 Vol. 43, No. 9 0095-1137/05/$08.00 0 doi:10.1128/jcm.43.9.4480 4485.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.

More information

AAC Accepts, published online ahead of print on 13 October 2008 Antimicrob. Agents Chemother. doi: /aac

AAC Accepts, published online ahead of print on 13 October 2008 Antimicrob. Agents Chemother. doi: /aac AAC Accepts, published online ahead of print on 13 October 2008 Antimicrob. Agents Chemother. doi:10.1128/aac.00931-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions.

More information

hydrophila strain ACCEPTED *Corresponding author. Department of Bacteriology, National Center for Epidemiology, 1097

hydrophila strain ACCEPTED *Corresponding author. Department of Bacteriology, National Center for Epidemiology, 1097 JCM Accepts, published online ahead of print on 26 March 2008 J. Clin. Microbiol. doi:10.1128/jcm.00047-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All

More information

Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Hong Kong. Title. Ho, PL; Tse, CWS; Lai, EL; Lo, WU; Chow, KH

Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Hong Kong. Title. Ho, PL; Tse, CWS; Lai, EL; Lo, WU; Chow, KH Title Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Hong Kong Author(s) Ho, PL; Tse, CWS; Lai, EL; Lo, WU; Chow, KH Citation International Journal Of Antimicrobial Agents, 2011, v. 37 n. 4, p.

More information

Antibiograms of resistant Gram-negative bacteria from Scottish CF patients $

Antibiograms of resistant Gram-negative bacteria from Scottish CF patients $ Journal of Cystic Fibrosis 3 (2004) 151 157 www.elsevier.com/locate/jcf Antibiograms of resistant Gram-negative bacteria from Scottish CF patients $ F.M. MacKenzie a, S.V. Smith a, K.E. Milne a, K. Griffiths

More information

NONFERMENTING GRAM NEGATIVE RODS. April Abbott Deaconess Health System Evansville, IN

NONFERMENTING GRAM NEGATIVE RODS. April Abbott Deaconess Health System Evansville, IN NONFERMENTING GRAM NEGATIVE RODS April Abbott Deaconess Health System Evansville, IN OBJECTIVES Discuss basic limitations to assessing carbapenem resistance in nonfermenting GNRs Discuss antimicrobial

More information

Revised AAC Version 2» New-Data Letter to the Editor ACCEPTED. Plasmid-Mediated Carbapenem-Hydrolyzing β-lactamase KPC-2 in

Revised AAC Version 2» New-Data Letter to the Editor ACCEPTED. Plasmid-Mediated Carbapenem-Hydrolyzing β-lactamase KPC-2 in AAC Accepts, published online ahead of print on 3 December 2007 Antimicrob. Agents Chemother. doi:10.1128/aac.01180-07 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions.

More information

(multidrug-resistant Pseudomonas aeruginosa; MDRP)

(multidrug-resistant Pseudomonas aeruginosa; MDRP) 220 2009 (multidrug-resistant Pseudomonas aeruginosa; MDRP) 21 4 1 21 10 4 amikacin (AMK), imipenem/cilastatin (IPM), ciprofloxacin (CPFX) multidrug-resistant Pseudomonas aeruginosa (MDRP) CHROMagar TM

More information

Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa G. M. Rossolini and E. Mantengoli

Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa G. M. Rossolini and E. Mantengoli Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa G. M. Rossolini and E. Mantengoli Dipartimento di Biologia Molecolare, Sezione di Microbiologia, Università degli

More information

Against Aerobic Gram-Negative Bacilli

Against Aerobic Gram-Negative Bacilli ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 1979, p. 6-6 0066-0/79/1-06/05$0.00/0 Vol., No. 6 In Vitro Activity of LY17935, a New 1-Oxa Cephalosporin, Against Aerobic Gram-Negative Bacilli DENNIS G. DELGADO,

More information

Surveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia

Surveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 41 41 Surveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia IRINA

More information

Chalhoub et al. Avibactam and resistance mechanisms in P. aeruginosa - Page 1 of 17

Chalhoub et al. Avibactam and resistance mechanisms in P. aeruginosa - Page 1 of 17 Chalhoub et al. Avibactam and resistance mechanisms in P. aeruginosa - Page 1 of 17 International Journal of Antimicrobial Agents (IJAA-D-17-00824) Short communication (In press) Loss of activity of ceftazidime-avibactam

More information

Rapid identification and resistance assessment: The future is mass spectrometry

Rapid identification and resistance assessment: The future is mass spectrometry Rapid identification and resistance assessment: The future is mass spectrometry Dr Sanmarié Schlebusch Director of Microbiology Mater Pathology Brisbane Outline Introduction Plug and play Pre-prep and

More information

Effect of efflux pump inhibitors on antimicrobial resistance and in vivo colonization of Campylobacter jejuni

Effect of efflux pump inhibitors on antimicrobial resistance and in vivo colonization of Campylobacter jejuni Effect of efflux pump inhibitors on antimicrobial resistance and in vivo colonization of Campylobacter jejuni J. Lin & M. Ensminger Department of Animal Science, The University of Tennessee, Knoxville,

More information

Expert rules in antimicrobial susceptibility testing: State of the art

Expert rules in antimicrobial susceptibility testing: State of the art Expert rules in antimicrobial susceptibility testing: State of the art ESCMID Postgraduate Education Course Antimicrobial Susceptibility Testing and Surveillance: from Laboratory to Clinic Hospital Universitario

More information

Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections ACCEPTED

Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections ACCEPTED AAC Accepts, published online ahead of print on August 00 Antimicrob. Agents Chemother. doi:./aac.000-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights

More information

Academic Perspective in. David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic resistance PHE

Academic Perspective in. David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic resistance PHE Academic Perspective in Emerging No, we can t Issues treat of carbapenemase Resistance and ESBL in Gram-ve producers Bacteria based on MIC David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic

More information

/01/$ DOI: /JCM Copyright 2001, American Society for Microbiology. All Rights Reserved.

/01/$ DOI: /JCM Copyright 2001, American Society for Microbiology. All Rights Reserved. JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2001, p. 183 190 Vol. 39, No. 1 0095-1137/01/$04.00 0 DOI: 10.1128/JCM.39.1.183 190.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Contemporary

More information

Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms

Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms CLINICAL MICROBIOLOGY REVIEWS, Oct. 2009, p. 582 610 Vol. 22, No. 4 0893-8512/09/$08.00 0 doi:10.1128/cmr.00040-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. Antibacterial-Resistant

More information

Author: Souha Kanj Andrew Whitelaw Michael J. Dowzicky. To appear in: International Journal of Antimicrobial Agents

Author: Souha Kanj Andrew Whitelaw Michael J. Dowzicky. To appear in: International Journal of Antimicrobial Agents t Title: In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011 Author: Souha Kanj Andrew Whitelaw

More information

High Incidence of Multidrug Resistant Pseudomonas aeruginosa Isolated from Infected Burn Wounds in a Tertiary Hospital

High Incidence of Multidrug Resistant Pseudomonas aeruginosa Isolated from Infected Burn Wounds in a Tertiary Hospital International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 2 (2017) pp. 1134-1139 Journal homepage: http://www.ijcmas.com Original Research Article http://dx.doi.org/10.20546/ijcmas.2017.602.128

More information

ACCEPTED. Comparison of disk diffusion and agar dilution methods for erythromycin and

ACCEPTED. Comparison of disk diffusion and agar dilution methods for erythromycin and AAC Accepts, published online ahead of print on January 00 Antimicrob. Agents Chemother. doi:./aac.000-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights

More information

JCM Accepts, published online ahead of print on 5 March 2008 J. Clin. Microbiol. doi: /jcm

JCM Accepts, published online ahead of print on 5 March 2008 J. Clin. Microbiol. doi: /jcm JCM Accepts, published online ahead of print on March 00 J. Clin. Microbiol. doi:0./jcm.00-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

More information

Disclosure. Objectives. Evolution of β Lactamases. Extended Spectrum β Lactamases: The New Normal. Prevalence of ESBL Mystic Program

Disclosure. Objectives. Evolution of β Lactamases. Extended Spectrum β Lactamases: The New Normal. Prevalence of ESBL Mystic Program 47 th Annual Meeting August 2-4, 2013 Orlando, FL Extended Spectrum β Lactamases: The New Normal Disclosure I do have a vested interest in or affiliation with the following companies or organizations Triax

More information

Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus

Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus Eur Respir J 2000; 16: 749±767 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 2000 European Respiratory Journal ISSN 0903-1936 CONSENSUS STATEMENT Antibiotic therapy against Pseudomonas

More information

Biofilms: Álvaro Pascual MD, PhD Department of Microbiology

Biofilms: Álvaro Pascual MD, PhD Department of Microbiology Biofilms: Role on Pathogenesis and Treatment of UTIs. Álvaro Pascual MD, PhD Department of Microbiology University of Seville. Spain. Medical devices-related infections 1. 35 millions/year in USA 2. Most

More information

Prevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital

Prevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital ISSN: 2319-7706 Volume 3 Number 10 (2014) pp. 474-478 http://www.ijcmas.com Original Research Article Prevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital

More information

MIC Test Strip for antimicrobial susceptibility testing

MIC Test Strip for antimicrobial susceptibility testing for antimicrobial susceptibility testing Liofilchem Liofilchem Quantitative assay for determining the Minimum Inhibitory Concentration (M.I.C.) is a quantitative assay for determining the Minimum Inhibitory

More information

PHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS

PHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS PHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS SITI HIR HURAIZAH MD TAHIR Bpharm (UKM), MSc (Clinical Microbiology) (UoN) CLINICAL PHARMACIST HOSPITAL MELAKA WHY STUDY PHARMACOKINETICS (PK) AND PHARMACODYNAMICS

More information

Sepsis new definitions of sepsis and septic shock and Novelities in sepsis treatment

Sepsis new definitions of sepsis and septic shock and Novelities in sepsis treatment Sepsis new definitions of sepsis and septic shock and Novelities in sepsis treatment What is sepsis? Life-threatening organ dysfunction caused by a dysregulated host response to infection A 1991 consensus

More information

In Vitro Activity of Ceftazidime-Avibactam Against Isolates. in a Phase 3 Open-label Clinical Trial for Complicated

In Vitro Activity of Ceftazidime-Avibactam Against Isolates. in a Phase 3 Open-label Clinical Trial for Complicated AAC Accepted Manuscript Posted Online 21 November 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.01820-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10

More information

without the permission of the author Not to be copied and distributed to others

without the permission of the author Not to be copied and distributed to others Emperor s Castle interior-prato What is the Role of Inhaled Polymyxins for Treatment of Respiratory Tract Infections? Helen Giamarellou CONCLUSIONS: Patients with Pseudomonas and Acinetobacter VAP may

More information

In-House Standardization of Carba NP Test for Carbapenemase Detection in Gram Negative Bacteria

In-House Standardization of Carba NP Test for Carbapenemase Detection in Gram Negative Bacteria International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 7 Number 01 (2018) Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2018.701.342

More information

The Effects of Berberine and Palmatine on Efflux Pumps Inhibition with Different Gene Patterns in Pseudomonas aeruginosa Isolated from Burn Infections

The Effects of Berberine and Palmatine on Efflux Pumps Inhibition with Different Gene Patterns in Pseudomonas aeruginosa Isolated from Burn Infections Original Article The Effects of Berberine and Palmatine on Efflux Pumps Inhibition with Different Gene Patterns in Pseudomonas aeruginosa Isolated from Burn Infections Seyed Sajjad Aghayan 1, Hamidreza

More information

Guidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011

Guidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011 Guidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011 Objectives: To discuss the guidelines for detection of CRE in the laboratory setting. To review

More information

Efficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis

Efficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis Efficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis Vallières, E., Tumelty, K., Tunney, M. M., Hannah, R., Hewitt, O., Elborn, J. S., & Downey, D. G. (2017). Efficacy of Pseudomonas

More information

Terapia delle infezioni da Pseudomonas aeruginosa MDR

Terapia delle infezioni da Pseudomonas aeruginosa MDR Verona 23 ottobre 2010 Terapia delle infezioni da Pseudomonas aeruginosa MDR Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Global resistance surveillance of Pseudomonas aeruginosa

More information

Therapeutic drug monitoring of β-lactams

Therapeutic drug monitoring of β-lactams CORATA Belgique Reims 1-2/10/2014 Therapeutic drug monitoring of β-lactams Frédéric Cotton Clinical Chemistry Erasme Hospital Faculty of Pharmacy ULB TDM of β-lactams β-lactams pharmacokinetics pharmacodynamics

More information

Resistance to Polymyxins in France

Resistance to Polymyxins in France Resistance to Polymyxins in France Paris Prof. Patrice Nordmann NDM producers in Enterobacteriaceae The polymyxins; colistin and polymyxin B Colistin - Synthesis by Bacillus polymyxa spp colistinus -

More information

Ceftazidime-Avibactam and Aztreonam an interesting strategy to Overcome β- Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae

Ceftazidime-Avibactam and Aztreonam an interesting strategy to Overcome β- Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae AAC Accepted Manuscript Posted Online 19 June 2017 Antimicrob. Agents Chemother. doi:10.1128/aac.01008-17 Copyright 2017 American Society for Microbiology. All Rights Reserved. 1 2 3 Ceftazidime-Avibactam

More information

HUSRES Annual Report 2009 Martti Vaara

HUSRES Annual Report 2009 Martti Vaara HUSRES Annual Report 2009 Martti Vaara www.huslab.fi www.intra.hus.fi Martti Vaara, 2/2010 1 The basis of this HUSRES 2009 report is the HUSLAB/Whonet database 2009, which contains susceptibility data

More information

Activity of Ceftolozane/Tazobactam Against a Broad Spectrum of Recent Clinical Anaerobic Isolates

Activity of Ceftolozane/Tazobactam Against a Broad Spectrum of Recent Clinical Anaerobic Isolates AAC Accepts, published online ahead of print on 25 November 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.02253-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. Activity

More information

Journal of Infectious Diseases and

Journal of Infectious Diseases and Journal of Infectious Diseases & Therapy ISSN: 2332-0877 Journal of Infectious Diseases and Therapy Santanirand et al., J Infect Dis Ther 2018, 6:5 DOI: 10.4172/2332-0877.1000378 Research Article Open

More information

Characterization of Mucoid and Non-Mucoid Streptococcus pneumoniae Isolated From Outpatients

Characterization of Mucoid and Non-Mucoid Streptococcus pneumoniae Isolated From Outpatients Original Article Clinical Microbiology Ann Lab Med 2015;35:410-415 http://dx.doi.org/10.3343/alm.2015.35.4.410 ISSN 2234-3806 eissn 2234-3814 Characterization of Mucoid and Non-Mucoid Streptococcus pneumoniae

More information

Inhalational antibacterial regimens in non-cystic fibrosis patients. Jeff Alder Bayer HealthCare

Inhalational antibacterial regimens in non-cystic fibrosis patients. Jeff Alder Bayer HealthCare Inhalational antibacterial regimens in non-cystic fibrosis patients Jeff Alder Bayer HealthCare Alder - Inhaled therapy for non-cf - EMA 25-26 Oct 2012 1 Inhalational antibacterials: two approaches 1.

More information

Detecting CRE. what does one need to do?

Detecting CRE. what does one need to do? 5 th ICAN Conference, Harare 4 th November 2014 Room 2: 10:30-12:00 Detecting CRE (Carbapenem-resistant Enterobacteriaceae) what does one need to do? Dr Nizam Damani Associate Medical Director Infection

More information

Molecular mechanisms of antibiotic resistance in Neisseria gonorrhoeae

Molecular mechanisms of antibiotic resistance in Neisseria gonorrhoeae medicaldaily.com http://en.vircell.com/diseases ppcorn.com Molecular mechanisms of antibiotic resistance in Neisseria gonorrhoeae Robert Nicholas University of North Carolina at Chapel Hill cdc.gov Timeline

More information

Research Article Antimicrobial Susceptibility Patterns of Pseudomonas aeruginosa from Diabetes Patients with Foot Ulcers

Research Article Antimicrobial Susceptibility Patterns of Pseudomonas aeruginosa from Diabetes Patients with Foot Ulcers Microbiology Volume 2011, Article ID 605195, 4 pages doi:10.1155/2011/605195 Research Article Antimicrobial Susceptibility Patterns of Pseudomonas aeruginosa from Diabetes Patients with Foot Ulcers Tamil

More information

Shannon Kasperbauer, M.D. National Jewish Health University of Colorado Health Sciences Center. Property of Presenter. Not for Reproduction

Shannon Kasperbauer, M.D. National Jewish Health University of Colorado Health Sciences Center. Property of Presenter. Not for Reproduction Shannon Kasperbauer, M.D. National Jewish Health University of Colorado Health Sciences Center Consultant: Johnson and Johnson Speaker/consultant: Insmed Examine characteristics of the RGM Define the main

More information

Adenium Biotech. Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes

Adenium Biotech. Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes Adenium Biotech Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes Board of Directors: - Stephan Christgau, PhD, chairman,

More information

ANTIPSEUDOMONAL ANTIBIOTICS

ANTIPSEUDOMONAL ANTIBIOTICS Use of this content is subject to the Terms and Conditions ANTIPSEUDOMONAL ANTIBIOTICS Medical Clinics of North America - Volume 85, Issue 1 (January 2001) - Copyright 2001 W. B. Saunders Company DOI:

More information

ALERT. Clinical microbiology considerations related to the emergence of. New Delhi metallo beta lactamases (NDM 1) and Klebsiella

ALERT. Clinical microbiology considerations related to the emergence of. New Delhi metallo beta lactamases (NDM 1) and Klebsiella ALERT Clinical microbiology considerations related to the emergence of New Delhi metallo beta lactamases (NDM 1) and Klebsiella pneumoniae carbapenemases (KPC) amongst hospitalized patients in South Africa

More information

Incidence of metallo beta lactamase producing Pseudomonas aeruginosa in ICU patients

Incidence of metallo beta lactamase producing Pseudomonas aeruginosa in ICU patients Indian J Med Res 127, April 2008, pp 398-402 Incidence of metallo beta lactamase producing Pseudomonas aeruginosa in ICU patients Ami Varaiya, Nikhil Kulkarni, Manasi Kulkarni, Pallavi Bhalekar & Jyotsana

More information

Phenotypic Detection Methods of Carbapenemase Production in Enterobacteriaceae

Phenotypic Detection Methods of Carbapenemase Production in Enterobacteriaceae ISSN: 2319-7706 Volume 4 Number 6 (2015) pp. 547-552 http://www.ijcmas.com Original Research Article Phenotypic Detection Methods of Carbapenemase Production in Enterobacteriaceae Sathya Pandurangan 1,

More information

Annual Surveillance Summary: Klebsiella species Infections in the Military Health System (MHS), 2017

Annual Surveillance Summary: Klebsiella species Infections in the Military Health System (MHS), 2017 i Annual Surveillance Summary: Klebsiella species Infections in the Military Health System (MHS), 2017 Tej Mishra and Uzo Chukwuma Approved for public release. Distribution is unlimited. The views expressed

More information

PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS

PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS Dr. J. Fernández. Head of the Liver Unit Hospital Clinic Barcelona, Spain AEEH Postgraduate Course, Madrid, February 15 2017 Prevalence of

More information

Determination of MIC & MBC

Determination of MIC & MBC 1 Determination of MIC & MBC Minimum inhibitory concentrations (MICs) are defined as the lowest concentration of an antimicrobial that will inhibit the visible growth of a microorganism after overnight

More information

Exogenous Pyocyanin Alters Pseudomonas aeruginosa Susceptibility to Ciprofloxacin

Exogenous Pyocyanin Alters Pseudomonas aeruginosa Susceptibility to Ciprofloxacin American Journal of Microbiology 1 (1): 9-13, 2010 ISSN 1948-982x 2010 Science Publications Corresponding Author: Exogenous Pyocyanin Alters Pseudomonas aeruginosa Susceptibility to Ciprofloxacin 1,2 Gary

More information

β-lactamase inhibitors

β-lactamase inhibitors β-lactamase inhibitors Properties, microbiology & enzymology DAVID M LIVERMORE Professor of Medical Microbiology, UEA Lead on Antibiotic Resistance, Public Health England β-lactamase classes A B C D Serine

More information

Use of imipenem. with the support of Wallonie-Bruxelles International. Magali Dodémont Microbiology Hospital Erasme Université Libre de Bruxelles

Use of imipenem. with the support of Wallonie-Bruxelles International. Magali Dodémont Microbiology Hospital Erasme Université Libre de Bruxelles with the support of Wallonie-Bruxelles International Use of imipenem Magali Dodémont Microbiology Hospital Erasme Université Libre de Bruxelles 1 Β-lactams classification 2 Β-lactams: mode of action Inhibition

More information

In vitro and Intracellular Activities of Peptide Deformylase. Inhibitor GSK against Legionella pneumophila Isolates

In vitro and Intracellular Activities of Peptide Deformylase. Inhibitor GSK against Legionella pneumophila Isolates AAC Accepts, published online ahead of print on 27 October 2014 Antimicrob. Agents Chemother. doi:10.1128/aac.04006-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 In vitro

More information

Insert for Kit 98006/98010/ KPC/Metallo-B-Lactamase Confirm Kit KPC+MBL detection Kit KPC/MBL and OXA-48 Confirm Kit REVISION: DBV0034J

Insert for Kit 98006/98010/ KPC/Metallo-B-Lactamase Confirm Kit KPC+MBL detection Kit KPC/MBL and OXA-48 Confirm Kit REVISION: DBV0034J Insert for Kit 98006/98010/98015 KPC/Metallo-B-Lactamase Confirm Kit KPC+MBL detection Kit KPC/MBL and OXA-48 Confirm Kit REVISION: DBV0034J DATE OF ISSUE: 09.02.2017 LANGUAGE: English FOR IN VITRO DIAGNOSTIC

More information

Pseudomonas aeruginosa: from environment to humans

Pseudomonas aeruginosa: from environment to humans Pseudomonas aeruginosa: from environment to humans Finovi Thursday 9 th december 2010, Lyon Jean Freney UMR 5557 CNRS Ecologie Microbienne University of Lyon 1 Pseudomonas aeruginosa Carle Gessard (1850-1925)

More information